Staidson | Balance Sheet

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
916
1,103
1,317
1,371
1,093
1,264
Total Accounts Receivable
276
342
376
436
378
212
Inventories
34
29
25
33
37
43
Other Current Assets
2
1
1
2
311
33
Total Current Assets
1,229
1,475
1,719
1,842
1,820
1,553
Net Property, Plant & Equipment
244
244
245
251
271
331
Total Investments and Advances
2
1
8
153
436
793
Intangible Assets
72
62
57
57
56
64
Other Assets
-
-
-
-
1
1
Total Assets
1,569
1,812
2,071
2,351
2,629
2,772
ST Debt & Current Portion LT Debt
-
-
57
60
27
Accounts Payable
4
7
4
6
5
Income Tax Payable
-
7
12
11
3
Other Current Liabilities
208
239
281
329
316
Total Current Liabilities
219
258
353
399
348
Deferred Taxes
11
18
36
42
21
Other Liabilities
-
-
-
-
15
Total Liabilities
231
269
359
405
387
Common Equity (Total)
1,314
1,514
1,665
1,902
2,209
Total Shareholders' Equity
1,314
1,514
1,665
1,902
2,209
Total Equity
1,314
1,514
1,684
1,918
2,209
Liabilities & Shareholders' Equity
1,569
1,812
2,071
2,351
2,629
Accumulated Minority Interest
-
-
19
16
-
Non-Equity Reserves
25
28
28
28
32

About Staidson

View Profile
Address
36 Jinghai 2nd Road
Beijing Beijing 100176
China
Employees -
Website http://www.staidson.com
Updated 07/08/2019
Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research, development, production, and sale of independent intellectual property innovation drugs. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin. The company was founded on August 16, 2002 and is headquartered in Beijing, China.